Cel-Sci Corporation - CVM

Cel-Sci Corporation (CVM)
http://www.cel-sci.com/
Coverage: June 13, 2009 - December 13, 2009
Featured: June 13, 2009

The WHO (I'm not kidding- World Health Organization) has officially declared the Swine Flu as a world wide pandemic. This past week, the WHO raised the Swine Flu to "Phase 6", it's highest level for global risk. The Phase 6 alert does not mean the severity is increasing- it means the spread is more global. The Phase 6 ranking opens the door to accelerated production and research on a number of possible therapies and vaccines.

One company getting major recognition for a possible therapy is AMEX listed Cel-Sci (AMEX: CVM), a stock I have been following on and off for many years. Last week, CVM announced its L.E.A.P.S (Ligand Epitope Antigen Presentation System) technology, could represent an immune based therapy for swine flu, and had shown promise. At the Naval Medical Research Center in Silver Spring, MD, L.E.A.P.S has demonstrated an ability to enhance the body's natural protection against many different kinds of diseases. The Navy is focused on using the therapy to treat Malaria. This past week, Cel-Sci announced it was developing an immune based treatment for the Swine Flu, and the stock went absolutely ballistic.

Cel-Sci traded 32 million shares in one day last week, the highest volume in its more than 20 years of being a publicly traded company under the ticker CVM. CVM also surged from about $.25 to $.80 in one day. Pretty crazy.

Latest Newsletter Editions

spacer
Sat, Jan 16, 2010 @ 09:01 am
The Biotech Buzz Rerun I looked for some recent small stock biotech winners. Check out the action in ECTE of late. $1.30 to $2.20 this month on increasing volume as the stock climbs the charts. There's a lot of action in these small biotechs right now. Do you believe in reincarnation? In the stock market...
Wed, Jan 13, 2010 @ 11:01 am
The China/Biotech Buzz It's been a very strong week for my China ideas, with several of the top choices delivering strong news and making new all time highs this week. Review and comments on the hot China ideas below. Biotechs are buzzing right now, and a great number of small cap/biotech stocks are...
Wed, Dec 2, 2009 @ 08:12 am
Coming Attractions You might recall an edition I published about a month ago suggesting it was time to step back, take a look at every idea, and set some cash aside to get past tax selling season and into December. The time has come. I suspect December will be a good month in the markets. Small stocks...
Mon, Nov 9, 2009 @ 02:11 pm
You Asked For It; You'll Get It As expected, lots of you read about my Interclick (NASDAQ: ICLK) idea over the weekend, and sent me the same comment: Why didn't you tell us about this one back in May when it was still under $1 on the Bulletin Board? Point taken- after all, isn't that the goal of investing...
Sat, Oct 10, 2009 @ 04:10 pm
A Couple More Updates: Cel-Sci (AMEX: CVM) and CalAmp (NASDAQ: CAMP) There's lots more action to cover from this past week, so let's get to two more of the actively traded ideas I have shared of late. Cel-Sci (NYSE AMEX: CVM): The Squawking and Finger Pointing Was Inevitable CVM, one of the hottest...

Click Here For More Newsletters on CVM

spacer

Latest Blog Entries

spacer

Quote Data

spacer
Last Trade: 0.7909 Bid: 0.7010
Last Size: 100 Ask: 0.8790
Trade Time: 4:00pm Bid x Ask Size: 100x1000
Change: down arrow -0.0292 (-3.56%) Day's Range: 0.78 - 0.89
Prev Close: 0.8201 52wk Range: 0.54 - 1.30
Open: 0.8200 P/E (ttm): N/A
Volume: 425,754 EPS (ttm): -0.4590
spacer [Chart]

Business Summary

spacer
CEL-SCI Corporation, a biotechnology company, engages in research and development of drugs and vaccines for the treatment of cancer and infectious diseases. The company’s primary product Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines under phase II clinical trail for the treatment of cancer. It also develops CEL-1000 peptide product with its Ligand Epitope Antigen Presentation System technology which is under preclinical stage for the protection/treatment of animals against herpes, malaria, viral encephalitis, and cancer. The company markets its products to cancer centers, physicians, and clinics involved in immunotherapy. CEL-SCI was founded in 1983 and is based in Vienna, Virginia.

Disclosure

spacer
TGR Group LLC, an affiliate of MarketByte LLC, has been paid a fee of 100,000 newly issued restricted shares by Cel-Sci Corporation, for coverage of the Company.

Recent News Headlines

spacer
NEW STORY CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants
Thu, 21 May 2015 21:34:31 GMT
[at noodls] - CEL-SCI ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS Vienna, VA, May 21, 2015 -- CEL-SCI Corporation (NYSE MKT: CVM)('CEL SCI' or the 'Company') today announced that it has commenced ...
CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants
Thu, 21 May 2015 20:32:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that it has commenced an offering of common stock and warrants. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed.
4:32 pm CEL-SCI Corp has commenced an offering of common stock and warrants; terms not disclosed
Thu, 21 May 2015 20:32:00 GMT
CEL SCI CORP Financials
Tue, 19 May 2015 17:04:19 GMT
NEW STORY CEL-SCI Receives Authorization to Conduct Its Phase 3 Multikine Trial in Italy
Wed, 13 May 2015 13:47:20 GMT
[at noodls] - CEL-SCI RECEIVES AUTHORIZATION TO CONDUCT ITS PHASE 3 MULTIKINE TRIAL IN ITALY Italy is 23rd country to authorize CEL-SCI's trial for patient enrollment Vienna, VA, May 11, 2015 -- CEL-SCI Corporation ...
CEL SCI CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Wed, 13 May 2015 13:01:49 GMT
CEL-SCI Receives Authorization to Conduct Its Phase 3 Multikine Trial in Italy
Wed, 13 May 2015 13:00:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that the Italian Medicines Agency has authorized the Company to commence patient enrollment for its ongoing Phase 3 trial of its investigational immunotherapy Multikine* in patients with advanced primary squamous cell carcinoma of the oral cavity/soft palate, a type of head and neck cancer.
NEW STORY CEL-SCI Receives Authorization to Conduct Its Phase 3 Multikine Trial in Spain
Mon, 11 May 2015 14:37:54 GMT
[at noodls] - CEL-SCI RECEIVES AUTHORIZATION TO CONDUCT ITS PHASE 3 MULTIKINE TRIAL IN SPAIN Spain is 22nd country to authorize CEL-SCI's trial for patient enrollment Vienna, VA, May 11, 2015 -- CEL-SCI Corporation ...
CEL SCI CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mon, 11 May 2015 13:55:13 GMT
CEL-SCI Receives Authorization to Conduct Its Phase 3 Multikine Trial in Spain
Mon, 11 May 2015 12:00:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that Spain’s Agency for Medicinal Products and Medicinal Devices has authorized the Company to commence patient enrollment for its ongoing Phase 3 trial of its investigational immunotherapy Multikine* in patients with advanced primary squamous cell carcinoma of the oral cavity/soft palate, a type of head and neck cancer.
10-Q for CEL-SCI Corp.
Mon, 11 May 2015 00:11:51 GMT
NEW STORY CEL-SCI Corporation Reports Second Quarter Fiscal Year 2015 Financial Results
Fri, 08 May 2015 22:43:19 GMT
[at noodls] - CEL-SCI CORPORATION REPORTS SECOND QUARTER FISCAL YEAR 2015 FINANCIAL RESULTS Vienna, VA, May 8, 2015 -- CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended March ...
CEL SCI CORP Files SEC form 10-Q, Quarterly Report
Fri, 08 May 2015 21:15:29 GMT
Cel-Sci reports 2Q loss
Fri, 08 May 2015 21:13:06 GMT
Cel-Sci reports 2Q loss
Fri, 08 May 2015 21:13:06 GMT
CEL-SCI Corporation Reports Second Quarter Fiscal Year 2015 Financial Results
Fri, 08 May 2015 21:00:00 GMT
[Business Wire] - CEL-SCI Corporation today reported financial results for the quarter ended March 31, 2015.
NEW STORY CEL-SCI Announces Proposed Public Offering of Common Stock
Wed, 06 May 2015 10:28:59 GMT
[at noodls] - CEL-SCI ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Vienna, VA, May 6, 2015 -- CEL-SCI Corporation (NYSE MKT: CVM)announced today that it has commenced an underwritten public offering of $35.0 million ...
CEL-SCI Announces Proposed Public Offering of Common Stock
Wed, 06 May 2015 10:00:00 GMT
[Business Wire] - CEL-SCI Corporation announced today that it has commenced an underwritten public offering of $35.0 million of its common stock. CEL-SCI intends to grant the underwriter a 30-day option to purchase up to an additional $5.25 million of its common stock.
NEW STORY CEL-SCI Reports 4th Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial
Fri, 01 May 2015 13:25:34 GMT
[at noodls] - CEL-SCI REPORTS 4TH CONSECUTIVE MONTH OF RECORD PATIENT ENROLLMENT IN 2015 FOR ITS PHASE III HEAD AND NECK CANCER TRIAL Nearly 50% of patients have now been enrolled in the global Phase III trial Vienna, ...
CEL-SCI Reports 4th Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial
Fri, 01 May 2015 12:00:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that in April it enrolled 31 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* .